Elisabeth Oelmann
Chief Tech/Sci/R&D Officer en NUCANA PLC .
Perfil
Elisabeth Oelmann holds the position of Senior VP-Medical & Clinical Development at NuCana Plc.
In her past career she occupied the position of Senior Medical Director at Kymab Ltd., Medical Director-Oncology Europe Region at PRA International LLC and Professor at Freie Universität Berlin.
Dr. Oelmann received a doctorate from the University of Münster.
Cargos activos de Elisabeth Oelmann
Empresas | Cargo | Inicio |
---|---|---|
NUCANA PLC | Chief Tech/Sci/R&D Officer | 01/09/2020 |
Antiguos cargos conocidos de Elisabeth Oelmann.
Empresas | Cargo | Fin |
---|---|---|
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Corporate Officer/Principal | - |
Freie Universität Berlin | Corporate Officer/Principal | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Formación de Elisabeth Oelmann.
University of Münster | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NUCANA PLC | Health Technology |
Empresas privadas | 2 |
---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Health Technology |